[
  {
    "ts": null,
    "headline": "US FDA Votes in Favor of Benefit-Risk Profile of Johnson & Johnson’s DARZALEX FASPRO",
    "summary": "On May 20, Johnson & Johnson (NYSE:JNJ) announced that the FDA Oncologic Drugs Advisory Committee/ODAC voted 6-2 in favor of the benefit-risk profile of single-agent DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adult patients with high-risk smoldering multiple myeloma (HR-SMM). This recommendation is a step towards potentially making DARZALEX FASPRO the first treatment to delay […]",
    "url": "https://finnhub.io/api/news?id=9ec8dc60d045d12a3f13358bf5ed9005dc816c52ad9e5fa742fa5c1dd2c57070",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748171267,
      "headline": "US FDA Votes in Favor of Benefit-Risk Profile of Johnson & Johnson’s DARZALEX FASPRO",
      "id": 134694320,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "On May 20, Johnson & Johnson (NYSE:JNJ) announced that the FDA Oncologic Drugs Advisory Committee/ODAC voted 6-2 in favor of the benefit-risk profile of single-agent DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for treating adult patients with high-risk smoldering multiple myeloma (HR-SMM). This recommendation is a step towards potentially making DARZALEX FASPRO the first treatment to delay […]",
      "url": "https://finnhub.io/api/news?id=9ec8dc60d045d12a3f13358bf5ed9005dc816c52ad9e5fa742fa5c1dd2c57070"
    }
  }
]